June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Comparison of Concomitant Administration of Dexamethasone in One Eye versus Fluocinolone Acetonide in the Fellow Eye in Patients with Similar Degrees of Diabetic Macular Edema
Author Affiliations & Notes
  • Yigit C Akduman
    Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Jacob D Grodsky
    Ophthalmology, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Eduardo B Rodrigues
    Ophthalmology, Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Footnotes
    Commercial Relationships   Yigit Akduman None; Jacob Grodsky None; Eduardo Rodrigues None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2499 – F0225. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yigit C Akduman, Jacob D Grodsky, Eduardo B Rodrigues; Comparison of Concomitant Administration of Dexamethasone in One Eye versus Fluocinolone Acetonide in the Fellow Eye in Patients with Similar Degrees of Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2499 – F0225.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In this case series, we outline and analyze the structural and tomographic changes in three cases of individuals that received a dexamethasone intravitreal implant (Ozurdex®) injection in one eye and a fluocinolone acetonide intravitreal implant (Iluvien®) injection in the fellow eye at the same time.

Methods : The three cases were studied retrospectively to evaluate the relative efficacy between the two drugs. Best corrected visual acuity (BCVA), intraocular pressure (IOP), and maximum macular thickness (MMT) with optical coherence tomography (OCT) were taken as measurements along the timeline of follow up for comparison between the treatments.

Results : Ozurdex® appeared to have a more pronounced and prompter effect when compared to Iluvien®. In two cases, Ozurdex® showed a quick onset with decreased MMT and improved BCVA within two months while Iluvien® took 4-6 months to provide a similar effect. The response to Ozurdex® demonstrated by these variables began to decrease by the fourth month of follow up, requiring repeat injection of medication. In the third case, where macular edema was less pronounced prior to treatment, Iluvien® provided a quick response that was sustained throughout a 22-month follow-up period. In this case, Ozurdex® also showed significant response in the fellow eye but required two additional doses to maintain this effect throughout the same 22-month period. In addition, the eyes injected with Ozurdex® appeared to maintain the structural integrity of the external limiting membrane (ELM) and photoreceptor outer segments (OS) throughout the follow-up period, while OCT of the eyes injected with Iluvien® began to demonstrate structural disintegration of these critical layers as soon as four months after injection.

Conclusions : In patients with significant macular edema, intravitreal injection of Ozurdex® appears to provide quicker and more significant improvement in macular thickness, as well as better preservation of the outer retinal layers, when compared to intravitreal injection of Iluvien®. Further controlled studies comparing these two drugs are necessary.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×